Abstract

The present invention relates to antibodies having specificity for BTN2 and uses thereof, in particular for the treatment of cancer.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Bile salts are steroid acids derived from cholesterol in the liver, are released into the gastrointestinal tract to aid in digestion and are thoroughly modified by the resident gut microbiota. Bile acids act as versatile signaling molecules with a variety In of endocrine functions and are linked to several diseases. In particular, serum and urinary bile salts represent biomarkers for early diagnostics of liver dysfunction, yet their current detection methods are impractical and hard to scale. Here the inventors engineered engineered synthetic bile salt receptors using VtrA as sensing domains connected to E. coli CadC system which activates transcription upon dimerization. The performance of the system was assayed for various selection of promoters and they can show that fine tunable response that may be reached by changing expression levels of the bile salt receptor. By performing multiple rounds of directed evolution of the VtrA sensor the inventors obtained a collection of variants with a lower limit of detection and a higher sensitivity. Finally, they show that their bactosensor can detect pathological bile-salt concentrations in samples from patients with liver dysfunction. The present invention thus relates to bile salts bactosensor and use thereof for diagnostic and therapeutic purposes.

IPC Classes  ?

• C07K 14/195 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to new dendrimers with thiophosphoramidate units and derivatives, their preparation method and their use.

IPC Classes  ?

• C07F 9/6593 - 1,3,5-Triaza-2,4,6-triphosphorines
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention provides SOCE inhibitors that are useful as therapeutic agents in a variety of applications. The present invention also relates to pharmaceutical compositions, products and kits comprising such SOCE inhibitors, and methods of using the SOCE inhibitors in the treatment of a variety of diseases.

IPC Classes  ?

• C07D 235/04 - Benzimidazoles; Hydrogenated benzimidazoles
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a compound of the following general formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug for inhibiting ferroptosis. The present invention relates to a compound of the following general formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug for inhibiting ferroptosis.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/444 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 39/06 - Free radical scavengers or antioxidants
• C07D 209/12 - Radicals substituted by oxygen atoms

Abstract

A method for the servo control of an optical device includes a cavity exhibiting resonance around a center frequency ƒc, a laser and a phase modulator, the method being designed to servo-control the cavity to the laser or vice versa and to compensate for an amplitude modulation introduced by the phase modulator, the method comprising, inter alia, the following steps: A. varying a difference δν between the optical frequency of the laser radiation and the center frequency, such that the optical frequency scans the resonance, the difference being controlled by a parameter of an element of the device, and for each difference δνi i. modulating, at a modulation frequency ƒmod, a phase of the laser radiation, through a modulation phase ϕmod, with the phase modulator, ii. injecting the phase-modulated radiation into the cavity, iii. using a photodiode to detect radiation reflected or transmitted by the cavity and generating an electrical signal (St, Sr) representative of the intensity of the detected radiation, iv. demodulating the electrical signal at the modulation frequency ƒmod by synchronously generating a first demodulated signal and a second demodulated signal representative of the demodulated electrical signal, respectively at a first demodulation phase ϕdem,1 and at a second modulation phase ϕdem,2ϕdem,2≈ϕdem,1k, where k∈[0; 2π] is different from the first phase, and by filtering the first and the second signal so as to retain only a DC component of the first demodulated signal Vϵ1, called error signal 1, and of the second demodulated signal Vϵ2, called error signal 2.

IPC Classes  ?

• H01S 3/00 - Lasers, i.e. devices using stimulated emission of electromagnetic radiation in the infrared, visible or ultraviolet wave range
• H01S 3/137 - Stabilisation of laser output parameters, e.g. frequency or amplitude by controlling devices placed within the cavity for stabilising of frequency
• H01S 3/139 - Stabilisation of laser output parameters, e.g. frequency or amplitude by controlling the mutual position or the reflecting properties of the reflectors of the cavity

Abstract

The present invention relates to the adoptive therapy using notably CAR-T cells. Here the inventors used a lentiviral vector approach to silence RINF expression in a shRNA- dependent manner and evaluate the consequences of RINF silencing on human CAR-T cells proliferation ex vivo and their functionality and capacity to eradicate tumor cells in vivo. More, the proposed methodology to improve CAR-T cells persistence and efficacy by disrupting RINF/CXXC5 is not restricted to patients suffering from hematological or solid cancers (anti- CD19, anti-EGFR, anti-BCMA…) but could be also used to improve the efficacy of ACT in non-cancer diseases by such as lupus (1), cardiac fibrosis (2) or aging related-disorders (3). Thus, the present invention relates to an immune cell characterized in that it is defective for RINF.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/725 - T-cell receptors
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The invention provides a pharmaceutical composition in oral liquid form, comprising vinorelbine, or a pharmaceutically acceptable salt thereof, and a cyclodextrin that is sulfobutylether-beta-cyclodextrin (SBE-beta-CD), preferably wherein at least 95%, vinorelbine, or said pharmaceutically acceptable salt thereof, is in form of an inclusion complex with said cyclodextrin.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 9/08 - Solutions
• A61K 31/00 - Medicinal preparations containing organic active ingredients

Abstract

Disclosed are crystalline hafnium oxide nanoparticles, a method for manufacturing same, and the uses thereof. The invention relates to crystalline hafnium oxide nanoparticles, characterized in that they bear amide molecules and/or at least one amide degradation product chosen from a carboxylic acid, an amine or an amino acid and/or residues of said molecules on their surface.

IPC Classes  ?

• C01G 27/00 - Compounds of hafnium

Abstract

The present invention relates to a process for the fluorination and/or cyclization of an amino alkene or alkyne in a continuous-stream microreactor. The invention also relates to a facility for performing such a process.

IPC Classes  ?

• C07D 209/08 - Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
• C07C 311/00 - Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
• C07D 211/14 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
• C07D 211/38 - Halogen atoms or nitro radicals
• C07D 215/06 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
• C07D 279/02 - 1,2-Thiazines; Hydrogenated 1,2-thiazines
• C07D 295/185 - Radicals derived from carboxylic acids from aliphatic carboxylic acids
• C07D 519/04 - Dimeric indole alkaloids, e.g. vincaleucoblastine
• C07D 213/12 - Preparation by ring-closure involving the use of ammonia, amines, amine salts, or nitriles from unsaturated compounds
• C07C 209/74 - Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton by halogenation, hydrohalogenation, dehalogenation, or dehydrohalogenation
• C07C 303/40 - Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups

Abstract

The invention primarily relates to a biobased polyurethane resin composition, characterised in that it is obtained by mixing a volume V1 of polyisocyanate phase and a volume V2 of polyol phase, and in that: - either the polyisocyanate phase includes at least two polyisocyanates, at least one of which is an isocyanate-terminated prepolymer that comprises at least 70% biobased carbons and the other comprises at least 60% biobased carbons, and the polyol phase includes at least one polyol that comprises at least 80% biobased carbons, - or the polyol phase includes at least two polyols that each comprise at least 80% biobased carbons, and the polyisocyanate phase includes at least one isocyanate-terminated prepolymer that comprises at least 70% biobased carbons. Preferentially, the number of isocyanate functions in the polyisocyanate phase is equal to the number of alcohol functions in the polyol phase. The invention also relates to a method for manufacturing such a composition, which method advantageously involves evaluating the equivalent reactive volumes of each compound. The invention lastly relates to a printed support at least partially covered with a dome of resin, which dome of resin is produced from said polyurethane resin composition.

IPC Classes  ?

• C08G 18/10 - Prepolymer processes involving reaction of isocyanates or isothiocyanates with compounds having active hydrogen in a first reaction step
• C08G 18/36 - Hydroxylated esters of higher fatty acids
• C08G 18/48 - Polyethers
• C08G 18/66 - Compounds of groups , , or
• C08G 18/72 - Polyisocyanates or polyisothiocyanates
• C08G 18/79 - Nitrogen characterised by the polyisocyanates used, these having groups formed by oligomerisation of isocyanates or isothiocyanates
• C09D 175/04 - Polyurethanes
• C09D 175/08 - Polyurethanes from polyethers
• C08L 75/04 - Polyurethanes

Abstract

The invention relates to the use of a lipophilic derivative of an aminopolycarboxylic acid as an extractant to extract at least one rare earth from an acidic aqueous solution. Applications: production of rare earths from concentrates derived from urban ores and, in particular, from concentrates from waste electrical and electronic equipment such as used or discarded NdFeB permanent magnets; production of rare earths from concentrates derived from natural ores or from concentrates derived from residues of natural ores.

IPC Classes  ?

• C22B 59/00 - Obtaining rare earth metals
• C22B 3/28 - Amines
• C22B 3/32 - Carboxylic acids
• C22B 3/26 - Treatment or purification of solutions, e.g. obtained by leaching by liquid-liquid extraction using organic compounds
• C22B 7/00 - Working-up raw materials other than ores, e.g. scrap, to produce non-ferrous metals or compounds thereof
• C07C 237/06 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms

Abstract

Chronic nephropathies, in particular tubulointertial nephropathy or tubulointertial nephropathy with fibrosis feature represent a real global public health concern. In particular, nephronophthisis (NPH) is an orphan genetic disease affecting the kidney. This recessive affection usually manifests with polyuria followed by a gradual reduction in kidney function related to progressive renal scarring. To date, no treatment is available for this affection. Now the inventors show that inhibition of the Hippo signalling pathway represents a new therapeutic avenue for the treatment of chronic nephropathies such as NPH. In particular, the inventors show that inhibition of MST1/2 or LATS1/2 reduces the NPH pro-inflammatory signature in mIMCD-3 renal cells even in response to uropathogenic bacteria. Thus the present invention relates to use of inhibitors of the Hippo signalling pathway for the treatment of chronic nephropathies.

IPC Classes  ?

• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The present application relates to ceramic/polymer hybrid solid electrolytes with improved interfacial strength, comprising a surface-dehydrated pre-treated ceramic.

IPC Classes  ?

• H01M 10/056 - Accumulators with non-aqueous electrolyte characterised by the materials used as electrolytes, e.g. mixed inorganic/organic electrolytes
• H01M 10/052 - Li-accumulators
• H01M 6/18 - Cells with non-aqueous electrolyte with solid electrolyte

Abstract

A catalytic system based on at least one rare-earth metallocene and an organomagnesium reagent as co-catalyst of formula RB—(Mg—RA)m—Mg—RB is provided. According to the formula, RB comprises a benzene nucleus substituted with the magnesium atom. One of the carbon atoms of the benzene nucleus ortho to the magnesium is substituted with a methyl, an ethyl or an isopropyl or forms a ring with the carbon atom which is its closest neighbour and which is meta to the magnesium. The other carbon atom of the benzene nucleus ortho to the magnesium is substituted with a methyl, an ethyl or an isopropyl. RA is a divalent aliphatic hydrocarbon-based chain, optionally interrupted with one or more oxygen or sulfur atoms or with one or more arylene groups. The m is a number greater than or equal to 1, preferably 1. The catalytic system allows the synthesis of dienic and/or ethylenic telechelic polymers.

IPC Classes  ?

• C08F 4/54 - Metals; Metal hydrides; Metallo-organic compounds; Use thereof as catalyst precursors selected from light metals, zinc, cadmium, mercury, copper, silver, gold, boron, gallium, indium, thallium, rare earths, or actinides together with other compounds thereof
• C08F 10/02 - Ethene

Abstract

A method for recognizing a pattern in an image including a training phase of an oscillatory neuron network, the oscillatory neuron network being adapted to output a pattern when an image is inputted, the oscillatory neuron network being implemented by a circuitry comprising oscillators linked by interconnections including at least one coupling resistance having a coupling resistance value, the oscillators being coupled by a sub-harmonic injection technique and coding the output by their relative phase difference, the coupling resistance values being learnt during the training phase by using Hebbian learning rules, and an operating phase wherein the trained oscillatory neuron network is used to recognize a pattern in an image, at least one of the training phase and the operating phase being computer-implemented.

IPC Classes  ?

• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
• G06V 10/94 - Hardware or software architectures specially adapted for image or video understanding

Abstract

The present invention relates to a device for measuring and/or modifying a surface of a sample, including a sample holder, including a first area configured to receive the sample fixedly mounted relative to the first area, a support, a first probe configured to detect a first parameter at a point of the surface and to generate a first measurement signal representative of the first parameter, and a second probe configured to detect a second parameter at a point of the surface, and to generate a second measurement signal representative of the second parameter, the first parameter being different from the second parameter, or one of the first probe and the second probe being configured to modify a third parameter of the surface at the point of the surface.

IPC Classes  ?

• G01Q 60/04 - STM [Scanning Tunnelling Microscopy] combined with AFM [Atomic Force Microscopy]
• G01Q 20/00 - Monitoring the movement or position of the probe
• G01Q 30/14 - Liquid environment
• G01Q 40/00 - Calibration, e.g. of probes
• G01Q 60/16 - Probes, their manufacture or their related instrumentation, e.g. holders
• G01Q 60/38 - Probes, their manufacture or their related instrumentation, e.g. holders

Abstract

A process for preparing a catalyst material, includes: (a) providing a support material having surface hydroxyl (OH) groups, the support material is ceria (CeO2), zirconia (ZrO2) or a combination, and the support material contains between 0.3 and 2.0 mmol OH groups/g of the support material; (b) reacting the support material with at least one of: (b1) a compound containing at least one alkoxy or phenoxy group bound though its oxygen atom to a metal element from Group 5 (V, Nb, Ta) or Group 6 (Cr, Mo, W); (b2) a compound containing at least one hydrocarbon group bound though a carbon atom to a metal element from Group 5 or 6; (b3) a compound containing at least one hydrocarbon group bound though a carbon atom to a metal element which is copper (Cu); and (c) calcining the product obtained in step (b).

IPC Classes  ?

• B01J 37/02 - Impregnation, coating or precipitation
• B01D 53/94 - Chemical or biological purification of waste gases of engine exhaust gases by catalytic processes
• B01J 21/06 - Silicon, titanium, zirconium or hafnium; Oxides or hydroxides thereof
• B01J 23/10 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of rare earths
• B01J 23/20 - Vanadium, niobium or tantalum
• B01J 23/22 - Vanadium
• B01J 23/28 - Molybdenum
• B01J 23/30 - Tungsten
• B01J 23/72 - Copper
• B01J 31/02 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
• B01J 31/16 - Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
• B01J 31/22 - Organic complexes
• B01J 37/08 - Heat treatment

Abstract

An electromagnetic waveguide, such as an optical fibre, including a hollow central core surrounded by a microstructured sheath formed by an assembly of elementary cells, the microstructured sheath also including at least two elementary cells, at least one intermediate element connecting the elementary cells, the intermediate element having a cross-section with an area less than or equal to 50% of the cross-sectional area of each of the cells that it connects, the intermediate element having a refractive index less than or equal to the refractive index of each of the elementary cells that it connects.

IPC Classes  ?

• G02B 6/032 - Optical fibres with cladding with non-solid core or cladding

Abstract

The invention relates to a process for treating, with a plasma, a composition comprising at least a first compound and a second compound, characterized in that said process comprises at least: generating, within an enclosure, a non-equilibrium plasma flow from a gas present in said enclosure, and treating the composition contained in said enclosure with said non-equilibrium plasma flow so as to extract at least a portion of said first compound.

IPC Classes  ?

• C22B 4/00 - Electrothermal treatment of ores or metallurgical products for obtaining metals or alloys
• C22B 7/00 - Working-up raw materials other than ores, e.g. scrap, to produce non-ferrous metals or compounds thereof
• H05H 1/46 - Generating plasma using applied electromagnetic fields, e.g. high frequency or microwave energy

Abstract

An optical structure comprising at least one stack having a central filter (1) and two sandwiching optical elements (2,3) between which the central filter (1) is interposed, wherein the central filter (1) is in a matrix material. The matrix material being doped with at least one doping agent, the central filter (1) and the two optical elements (2,3) on either side thereof being assembled by bonding layers (4a, 4b) of a material based on the same matrix material as that of the central filter, the optical elements (2,3) on either side of the central filter (1) and the bonding layers (4a, 4b) each having a refractive index equal to that of the material of the central filter or only differing from this refractive index within a range of plus or minus 0.05, preferably within a range of plus or minus 0.02.

IPC Classes  ?

• G02B 5/28 - Interference filters
• G02B 1/11 - Anti-reflection coatings
• G02F 1/35 - Non-linear optics

Abstract

The invention relates to a cell culture comprising a placental cell and a culture medium consisting of minimal essential nutriments and a low amount of serum. The invention also relates to a method using the cell culture for identifying endocrine disruptor.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
• C12N 5/073 - Embryonic cells or tissues; Foetal cells or tissues
• G01N 33/74 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones

Abstract

The present disclosure is related to systems and methods of enzymatic degradation of crystallizable polymers or copolymers and PC/IPM containing crystallizable polymers or copolymers.

IPC Classes  ?

• C08J 11/10 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation
• C08J 11/06 - Recovery or working-up of waste materials of polymers without chemical reactions
• C12N 9/18 - Carboxylic ester hydrolases
• C12N 9/20 - Triglyceride splitting, e.g. by means of lipase
• C12N 9/50 - Proteinases
• C12N 9/80 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides
• B29B 17/00 - Recovery of plastics or other constituents of waste material containing plastics
• B02C 19/00 - Other disintegrating devices or methods

Abstract

The present invention relates a therapeutic combination of a BTN3A activating antibody, a Bcl-2 family inhibitor and hypomethylating agents that is particularly useful for the treatment of cancer, in particular hematological malignancies. The present disclosure more particularly relates to the combined use of a BTN3A activating antibody that activates the cytolytic function of Vγ9Vδ2 T cells, and of Venetoclax, which selectively inhibits the Bcl2 receptor, and hypomethylating agents such as Azacytidine, to promote synergistically and specifically Vγ9Vδ2 T cell anticancer activity.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Circulatory failure generates hypoxia and leads to accumulation of reductive species in tissue and circulatory failure monitoring tools are needed but rare. Cardiopulmonary bypass (CPB) is known to promote brief circulatory failure during its initiation. In the present study, the Inventors demonstrate a correlation between whole blood redox potential and circulatory failure during (CPB). They made a prospective study with 17 patients eligible for cardiac surgery with cardiopulmonary bypass. They demonstrated a frank reduction of the whole blood redox potential during circulatory failure during the initiation of CPB. They also demonstrated that they were able to classify patients in 3 groups, one of them presenting an unfavorable post-operative outcome. Accordingly, the present invention relates to a method of diagnosing acute circulatory failure in a patient comprising determining the level of redox potential in a sample obtained from said patient, wherein the level of redox potential indicates whether the patient suffers or not from an acute circulatory failure.

IPC Classes  ?

• G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor

Abstract

The invention relates to an optical substrate (1) having an integrated waveguide (2), at least one antenna (330) being formed in the optical substrate (1), the at least one antenna being formed by a plurality of nanoholes (341, 342, 343), at least one of the nanoholes (341, 342, 343) differing from the other nanoholes (341, 342, 343) by at least one of: its diameter, its spacing of the waveguide (2) in the height direction of the optical substrate (1), and its distance from an adjacent nanohole of the same antenna in the longitudinal direction of the optical substrate (1). The invention also relates to a spectrometer (S) that integrates an optical substrate (1) of this kind.

IPC Classes  ?

• G02B 6/12 - Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type of the integrated circuit kind
• B82Y 20/00 - Nanooptics, e.g. quantum optics or photonic crystals
• G02B 6/124 - Geodesic lenses or integrated gratings
• G02B 6/293 - Optical coupling means having data bus means, i.e. plural waveguides interconnected and providing an inherently bidirectional system by mixing and splitting signals with wavelength selective means

Abstract

Method for determining an amount of lithium contained in a biological fluid, said method comprising the steps consisting in adding, to a biological fluid sample of known volume, a given volume of a discriminating solution, the effect of which is to obtain a biological fluid solution buffered at a pH of between 6 and 8 and to bring about precipitation of at least a portion of the cations contained in the biological fluid sample except for the lithium Ions. The method further comprises the steps consisting in depositing a given volume of biological fluid solution onto an active layer (2) of an optode (1), said active layer comprising a chemical transducer of which at least one optical property is modified In the presence of lithium ions in the biological fluid solution, in measuring at least one characteristic of at least one light wave emitted or reflected by the active layer of the optode and in determining, from the at least one measured characteristic and from calibration data, an amount of lithium contained in the biological fluid.

IPC Classes  ?

• G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
• G01N 21/82 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a precipitate or turbidity

Abstract

A novel method for synthesizing NCA compounds. Also, a new use of a peptide coupling agent. The method makes it possible to obtain NCA compounds from α-amino-acids, under mild and non-racemic reaction conditions, and in the absence of constraining reagents of use, such as phosgene, which may lead to the formation of undesirable by-products.

IPC Classes  ?

• C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 263/06 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
• C07D 498/04 - Ortho-condensed systems

Abstract

The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
• C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
• C12N 9/22 - Ribonucleases
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The invention relates to a method of directional self-assembly lithography, said method comprising a step of depositing a block copolymer film on a layer (20) neutral with respect the block copolymer, said block copolymer film being for use as a lithography mask, said method being characterized in that it comprises the following steps of: depositing said neutral layer (20) on a surface of a substrate (10), said neutral layer (20) being of the carbon or fluoro-carbon type deposited to a thickness greater than 1.5 times the thickness of the block copolymer film (40), crosslinking said neutral layer, depositing said block copolymer film, comprising at least one silylated block, on said crosslinked neutral layer (30), subjecting the stack to an assembly temperature in order to nanostructure said block copolymer, removing (G1) at least one of the nano-domains (41, 42) from the nanostructured block copolymer film (40), in order to create a pattern intended to be transferred by etching (G2, G3, G4) into the thickness of the substrate (10).

IPC Classes  ?

• G03F 7/00 - Photomechanical, e.g. photolithographic, production of textured or patterned surfaces, e.g. printed surfaces; Materials therefor, e.g. comprising photoresists; Apparatus specially adapted therefor

Abstract

Deposition of a material such as indium in the form of nitrided thin layers, by evaporation and dual activation using a nitrogen plasma (41) and an electron beam (42).

IPC Classes  ?

• C23C 14/00 - Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material
• C23C 14/06 - Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material characterised by the coating material
• C23C 14/26 - Vacuum evaporation by resistance or inductive heating of the source
• C23C 14/24 - Vacuum evaporation
• C23C 14/32 - Vacuum evaporation by evaporation and subsequent ionisation of the vapours
• H01J 37/32 - Gas-filled discharge tubes

Abstract

The invention relates in particular to a cell culture device comprising an insert (1) having an internal cavity (11) delimited by an insert side wall (12) and an insert bottom (10), said internal cavity being able to receive said cell culture in a cell culture fluid so as to create a cell tissue (2). The device comprises a container (3) that removably receives said insert, said side wall (12) having first through-holes (13). The container comprises an internal flue (30) and an opening (33) which allows said insert (1) to be inserted into said flue. The insert bottom comprises second through-holes (14) allowing observation of the cells therethrough, said first and second through-holes being capillary holes able to retain said cell culture fluid in said internal cavity and serving to anchor said cell tissue.

IPC Classes  ?

• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means

Abstract

A method for optimizing a quantum operation to be applied on two quantum objects of a system of quantum objects The present invention relates to a method for optimizing a quantum operation to be applied on at least two quantum objects (12) of a system (10) of quantum objects, the method comprising the determination of an optimized pulse to be generated by at least one controlled laser for implementing the quantum operation on the at least two quantum objects (12) while fulfilling a robustness criterion, the at least two quantum objects (12) having a quantum state depending on the excitation level of the at least two quantum objects, the excitation level being chosen between 01, 10 and 11, 0 defining a de-excited state for a quantum object and 1 defining an excited state for a quantum object, the quantum state having a zero order term and a first order term.

IPC Classes  ?

• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control

Abstract

The invention relates to an optical device for the full-field optical coherence tomography microscopic imaging of at least one sample, the device comprising a lens for observing the sample when in use, the device comprising a specular interface, the device thus being able, when in use, to allow the production of at least one interference between at least one reference wave obtained by the reflection of light emitted by a light source associated with the device from the specular interface, and at least one object wave obtained by the backscattering of the light emitted by the source from the sample, the specular interface being arranged with respect to the lens in such a way that, when in use, the object wave passes through the specular interface on its path between the sample and the source. The invention also relates to the corresponding facility and method.

IPC Classes  ?

• G01B 9/02056 - Passive reduction of errors
• G01B 9/02091 - Tomographic interferometers, e.g. based on optical coherence
• G01B 9/04 - Measuring microscopes
• G01N 21/47 - Scattering, i.e. diffuse reflection
• G02B 21/00 - Microscopes
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons

Abstract

One aspect of the invention relates to a method (100) for controlling a mechatronic system, based on a model for predicting the behaviour of the mechatronic system and a cost function ensuring compliance with constraints by the mechatronic system, with a view to following path instructions to a prediction horizon, the method comprising: reformulating (10) the constraints into barrier functions and integrating the barrier functions into the cost function; and for each sampling period of a sequence of sampling periods: obtaining (20) the path instructions and at least one measurement of the mechatronic system in a current state; determining (30) coefficients of a polynomial of order m using a Nelder-Mead method optimizing the cost function based on the predicting model, this determining step receiving as input the path instructions and the at least one measurement of the mechatronic system obtained (20); computing (40) a command through evaluation of the polynomial; and applying (50) the command to the mechatronic system.

IPC Classes  ?

• G05B 13/02 - Adaptive control systems, i.e. systems automatically adjusting themselves to have a performance which is optimum according to some preassigned criterion electric
• G05B 13/04 - Adaptive control systems, i.e. systems automatically adjusting themselves to have a performance which is optimum according to some preassigned criterion electric involving the use of models or simulators

Abstract

transOPA1e.g., ex vivoin vivoOPA1OPA1 mutations.

IPC Classes  ?

• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A61P 27/02 - Ophthalmic agents
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention relates to the method for producing a three-dimensional (3D) model of multiple myeloma (MM), in the form of spheroids, by co-culturing stem cells/mesenchymal stromal cells, endothelial progenitors and primary plasma cells of one or more MM patients. The present invention also relates to the spheroids obtained by said method, and uses thereof.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/0781 - B cells; Progenitors thereof
• C12N 5/0775 - Mesenchymal stem cells; Adipose-tissue derived stem cells

Abstract

The present invention relates to a method for ultrasound imaging of a microvascular structure, which method characterised in that it comprises: - a step of injecting ultrasound contrast agents into blood vessels in a region comprising a microvascular structure, - a step of ultrasound imaging the region comprising the microvascular structure while the contrast agents flow through the blood vessels, the concentration of the contrast agents and/or the ultrasound frequency of the imaging being chosen such that the contrast agents are sufficiently separated to prevent feedback, - a step of detecting/filtering and locating the contrast agents, - a step of individually monitoring the contrast agents, - a step of classifying the behaviours of the individually monitored contrast agents according to at least one predetermined behaviour characteristic of contrast agents flowing through the microvascular structure, and - a step of imaging the microvascular structure according to the thus-performed classification.

IPC Classes  ?

• A61B 8/08 - Detecting organic movements or changes, e.g. tumours, cysts, swellings
• A61B 8/06 - Measuring blood flow

Abstract

The present invention relates to a method for identifying potentially relevant markers in cancer diagnosis, prognosis and/or therapy, comprising an analysis approach which is based on the detection of variations in methylation of ribosomal RNAs in a biological sample. The present invention also relates to several applications of this analysis approach for determining the cancer subtype and/or the prognosis of a patient suffering from cancer, for estimating or assessing the benefit of a treatment in such patient, but also for selecting one or more therapeutic drug(s) targeting ribosomes useful for treating cancers.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present invention relates to an isolated double stranded DNA polynucleotide that forms triplex with sequence 5′-GGUGGCAGCAAGAGAAAAAUGAGGAAGAAGCAAAAGCGGAAA-3′ (SEQ ID NO: 1) of the long non-coding RNA ANRIL (Antisense Non-coding RNA in the INK4 Locus). It also relates to a vector comprising the double stranded DNA polynucleotide, and to a pharmaceutical composition comprising the double stranded DNA polynucleotide or the vector. The present invention relates as well to the isolated double stranded DNA polynucleotide for use in the treatment of myocardial infarction, aneurysms, stenosis, myocardial infarction, aneurysms, cancers, eye diseases or type 2 diabetes.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 35/00 - Antineoplastic agents
• C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Abstract

A system for characterizing a pulse of electromagnetic radiation by time-resolved optical gating, which includes an interference-forming device which is adapted for superimposing four parts of the pulse. The system also includes a matrix image sensor which selectively captures, based on two-photon absorptions, an interference pattern formed by the pulse. The system allows obtaining the pulse shape completely and accurately, and is particularly suitable for characterizing ultrashort pulses. Also, the two-photon absorption can be produced in the matrix image sensor, or replaced by optical frequency doubling which is produced by an SHG crystal plate.

IPC Classes  ?

• G01J 11/00 - Measuring the characteristics of individual optical pulses or of optical pulse trains
• G02B 5/20 - Filters
• H04N 23/12 - Cameras or camera modules comprising electronic image sensors; Control thereof for generating image signals from different wavelengths with one sensor only

Abstract

An electrode including a storage film. The storage film includes a layer of a support material including at least one inclusion in which a compound of interest is stored and a wall of permeable sealing material sealing the at least one inclusion. The storage film further includes a porous layer covering, at least in part, the wall of sealing material, at least a portion of a surface of the porous layer constituting an active surface of the electrode.

IPC Classes  ?

• H01M 8/16 - Biochemical fuel cells, i.e. cells in which microorganisms function as catalysts

Abstract

The present invention relates to a synergistic combination of an FXR agonist and interferon for the treatment of hepatitis B.

IPC Classes  ?

• A61K 38/21 - Interferons
• A61K 31/4162 - 1,2-Diazoles condensed with heterocyclic ring systems
• A61K 31/42 - Oxazoles
• A61K 31/46 - 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• A61P 31/20 - Antivirals for DNA viruses

Abstract

Radically polymerizable dental material, which includes a catalyst paste and a base paste, wherein the catalyst pastes includes an oxidizing agent, preferably a peroxide or hydroperoxide, a radically polymerizable monomer and/or oligomer with acid group and a polyfunctional radically polymerizable monomer, and the base paste comprises a polyfunctional radically polymerizable monomer without an acid group and a dihydropyridine derivative of Formula (1) Radically polymerizable dental material, which includes a catalyst paste and a base paste, wherein the catalyst pastes includes an oxidizing agent, preferably a peroxide or hydroperoxide, a radically polymerizable monomer and/or oligomer with acid group and a polyfunctional radically polymerizable monomer, and the base paste comprises a polyfunctional radically polymerizable monomer without an acid group and a dihydropyridine derivative of Formula (1) Radically polymerizable dental material, which includes a catalyst paste and a base paste, wherein the catalyst pastes includes an oxidizing agent, preferably a peroxide or hydroperoxide, a radically polymerizable monomer and/or oligomer with acid group and a polyfunctional radically polymerizable monomer, and the base paste comprises a polyfunctional radically polymerizable monomer without an acid group and a dihydropyridine derivative of Formula (1) The material has good mechanical properties and does not exhibit a bitter taste.

IPC Classes  ?

• A61K 6/891 - Compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• A61K 6/61 - Cationic, anionic or redox initiators
• A61K 6/62 - Photochemical radical initiators
• A61K 6/77 - Glass

Abstract

A method for monitoring a hadron beam during hadron-therapy treatment of a subject including tumour cells labelled with a radiopharmaceutical product, in which the hadron beam includes a plurality of discrete hadron bursts, the method including the following steps: when a burst impacts on the subject, detecting the prompt gamma generated by the interaction of the hadrons of the burst with the tissues of the subject using a Compton telescope and reconstructing an image of the interaction volume; when no burst impacts on the subject, extracting the position of the tumour cells labelled with the radiopharmaceutical product using the Compton telescope and reconstructing an image of the total volume of the tumour; comparing the image of the interaction volume and the image of the total volume of the tumour so as to locate the measured interaction volume relative to the measured total volume of the tumour.

IPC Classes  ?

• A61N 5/10 - X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Abstract

The present invention relates to a kit and an in vitro method for detecting and characterizing the degradation of a particular organ or tissue, on the basis of the analysis of the presence of at least one specific methylated cell-free DNA in a biological sample. More particularly, the invention relates to a kit and a method for detecting and characterizing the degradation of an organ selected from: the brain, the lung and the kidney, and/or of a tissue present in this organ. The invention also relates to a method for the in vitro diagnosis of a disease or condition involving the lysis of an organ or tissue.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

222 in a sample, wherein the sample comprises a persistent luminescence nanoparticle.

IPC Classes  ?

• G01N 21/64 - Fluorescence; Phosphorescence
• G01N 21/77 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
• C01G 15/00 - Compounds of gallium, indium, or thallium
• G01N 33/84 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
• G01N 21/76 - Chemiluminescence; Bioluminescence
• G01N 21/70 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light mechanically excited, e.g. triboluminescence
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances

Abstract

The invention relates to a method (100) for assisting the determination of a dosage of antioxidants to be administered to a patient suffering from oxidative stress, said method (100) comprising at least one iteration of a prediction phase (108) comprising the following steps: - measurement (110), on a blood sample previously taken from said patient, of a level of at least the following input parameters: cholesterol level, zinc level, copper level, vitamin C level, vitamin E level, and selenium level; - estimation (130) of a dosage for at least one antioxidant to be administered to said patient, via a previously trained estimation model, executed by a calculation unit, said estimation model taking as input said at least one input parameter. The invention also relates to a device which implements such a method.

IPC Classes  ?

• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients

Abstract

The present invention relates to a microfluidic device and to a method for applying at least one hydrodynamic stress of defined intensity and duration to cells in suspension, said cell being in motion in said device, and for characterizing the morphology and the physiological state of these cells during, and optionally after, the application of the hydrodynamic stress.

IPC Classes  ?

• G01N 15/14 - Electro-optical investigation
• C12M 1/42 - Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic wave
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers

Abstract

The present invention relates to a method for producing or identifying one or several shared cancer epitope(s), as well as peptides comprising or consisting of the epitopes identified or produced by said method, expression vectors encoding said peptides, cytotoxic T lymphocytes (CTLs) generated in vitro by stimulation of T cells with the said peptides or vectors, CTLs of a subject treated with said peptides or vectors, and engineered T cells expressing T-cell receptors recognizing said peptides. The present invention also relates to the use of said peptides, expression vectors, CTLs or engineered T cells as a vaccine or a medicament, and in particular, the use of said peptides, expression vectors, CTLs, or engineered T cells for preventing or treating at least one cancer in a subject in need thereof.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• A61P 37/04 - Immunostimulants

Abstract

Oil-in-water Pickering emulsion comprising: an oil phase comprising a first therapeutic agent, an aqueous phase, polyester nanoparticles comprising a second therapeutic agent, wherein the oil phase is in the form of droplets and is dispersed in a continuous aqueous phase, and wherein at least a portion of the nanoparticles are localized at an interface between the oil phase and the aqueous phase, characterized in that the aqueous phase comprises hyaluronan. This new emulsion allows the topical treatment of inflammatory dermatoses such as psoriasis, atopic dermatitis or prurigo, benign skin inflammations such as inflammatory acne, scalp pathologies such asalopecia, dermo-cosmetic conditions, such as very dry irritable skin, tumor pathologies such as mycosis fungoides (indolent cutaneous T lymphoma) or cutaneous mastocytosis (accumulation and abnormal proliferation of mast cells in the dermis, with intense pruritus), and fibrosing pathologies such as keloids (raised, pruritic dystrophic scars, which have the particularity of not regressing spontaneously and of being able to extend beyond the traumatic/injured area).

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/107 - Emulsions
• A61K 9/51 - Nanocapsules
• A61K 47/36 - Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 38/13 - Cyclosporins
• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61K 31/515 - Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
• A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
• A61K 31/355 - Tocopherols, e.g. vitamin E
• A61P 17/00 - Drugs for dermatological disorders

Abstract

123412344, other than hydrogen, comprise from 1 to 30 carbon atoms, optionally substituted with at least one of the groups or substituents.

IPC Classes  ?

• C07D 307/68 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• A61Q 19/00 - Preparations for care of the skin
• C10M 105/00 - Lubricating compositions characterised by the base-material being a non-macromolecular organic compound

Abstract

A system to localize a micro-device inside a target body part, including: a micro-device remotely steered and controlled from outside the target body part, a control unit including a memory for storing one ultrasound image of the target body part, one probe being brought in contact with a securing body part of the patient, and at least one tracker connected to the micro-device. The probe and the tracker communicate with ultrasounds, the control unit being thus able to localize, in real time, the tracker within an internal referential defined with regards to the probe, and the control unit displays, on a screen, the ultrasound image and displays, in real time, the localization of the micro-device on the ultrasound image.

IPC Classes  ?

• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
• A61B 8/08 - Detecting organic movements or changes, e.g. tumours, cysts, swellings
• A61B 34/20 - Surgical navigation systems; Devices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
• A61B 17/00 - Surgical instruments, devices or methods, e.g. tourniquets

Abstract

Glycosylphosphatidylinositol (GPI) is a glycolipid that anchors more than 150 proteins to the cell surface. Pathogenic variants in several genes that participate in GPI biosynthesis cause inherited GPI deficiency (IGD) disorders. Here, the inventors reported that homozygous null alleles of PIGG, a gene involved in GPI modification, are responsible for the rare Emm-negative blood phenotype. Using a panel of K562 cells defective in both the GPI-transamidase and GPI remodeling pathways, they demonstrate that the Emm antigen, whose molecular basis has remained unknown for decades, is carried only by free GPI and that its epitope is composed of the second and third ethanolamine of the GPI backbone. Importantly, the inventors show that the decrease in Emm expression in several IGD patients is indicative of GPI defects. Overall, our findings establish Emm as a novel blood group system and have important implications for understanding the biological function of human free GPI.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• G01N 33/80 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types

Abstract

The present invention relates to a conjugated compound comprising a marker M pharmaceutically acceptable, and a peptide or pseudo-peptide P having at most 30 amino acid residues and able to bind the Low-Density Lipoprotein Receptor (LDLR) and to its use in a method of labelling and/or detecting and/or treating cancerous cells in a subject by administration of the conjugated compound to the subject an analysis of the presence and/or the amount of marker.

IPC Classes  ?

• A61K 51/08 - Peptides, e.g. proteins
• A61K 51/04 - Organic compounds
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
• G01N 33/60 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
• G01N 33/92 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol

Abstract

A chimeric antigen receptor including: a binding domain, the full DAP 10 protein, the full DAP 12 protein, or a functional variant thereof, and a hook binding domain. Also, a vector system comprising one or more vector including: a nucleic acid comprising a nucleic acid sequence encoding a chimeric antigen receptor and optionally a nucleic acid encoding a hook fusion protein, preferably having a streptavidin core; wherein the nucleic acids are located on the same or on different vectors. Further, a lentiviral vector particles system, host cell and kit including the nucleic acids or vector system, and their use as a medicament, notably for immunotherapy.

IPC Classes  ?

• C07K 14/435 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
• C12N 15/86 - Viral vectors

Abstract

The invention relates to a measuring device (10) for measuring physical characteristics of cells. The device (10) comprises: a microfluidic chip (20) provided with a flow channel (22) for allowing cells to flow through; a manipulator (24) configured to apply deformation force to a cell in a continuous flow; and a sensor (26) configured to sense a physical characteristic of the cell. The manipulator (24) and the sensor (26) are configured to define a width (W2) of the flow channel (22) as a gap formed between them. The manipulator (24) is configured to apply the deformation force to the cell by compressing the cell against the sensor (26).

IPC Classes  ?

• G01N 15/14 - Electro-optical investigation
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
• G01N 15/10 - Investigating individual particles
• G01N 33/487 - Physical analysis of biological material of liquid biological material

Abstract

Positive electrodes based on organic active material, including molecules of thianthrene as the active material, substituted at specific positions. The electrodes have electrochemical properties enabling their use in a battery, in particular a recyclable battery. The electrodes thus replace the electrodes based on mineral salts that are conventionally used in batteries.

IPC Classes  ?

• H01M 4/60 - Selection of substances as active materials, active masses, active liquids of organic compounds
• H01M 4/04 - Processes of manufacture in general
• H01M 4/139 - Processes of manufacture
• H01M 10/052 - Li-accumulators
• H01M 10/0568 - Liquid materials characterised by the solutes
• H01M 10/0569 - Liquid materials characterised by the solvents

Abstract

The present invention relates to a process for tanning hides using a tanning solution that comprises a silicon compound and is free from metals. The invention also relates to a method for preparing leather that includes a tanning process of this type. The invention also relates to tanned hides obtained by such a tanning process. The invention further relates to a process for detanning the hides obtained by means of the above tanning process.

IPC Classes  ?

• C14C 3/08 - Chemical tanning by organic agents

Abstract

5242323333.

IPC Classes  ?

• C07F 5/06 - Aluminium compounds
• C07F 15/02 - Iron compounds
• B01D 53/02 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography
• B01J 20/22 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material

Abstract

The invention relates to an elementary particle detector (1) comprising: dynodes (10) capable of converting an elementary particle into an avalanche of electrons; conductive grids (30) through which accelerated electrons are able to pass, each grid being defined by a unique electric potential, each unique electric potential being chosen so that the unique electric potential of said conductive grid (30) is strictly lower than the unique electric potential applied to the conductive grid (30) immediately thereafter in the direction of detection (X); at least one signal sensor (50) able to measure an electric signal (S) produced by the accelerated electrons when they pass through the conductive grids (30); and a control unit (90) configured to determine, on the basis of the electric signal (S), a conversion dynode (18) at which the conversion of the elementary particle has taken place. The invention further relates to an elementary particle detection method.

IPC Classes  ?

• H01J 43/24 - Dynodes having potential gradient along their surfaces
• H01J 43/30 - Circuit arrangements not adapted to a particular application of the tube and not otherwise provided for
• H01J 47/02 - Ionisation chambers

Abstract

A method for isolating a mammalian genomic DNA replication origin, the method including: isolating the genomic DNA molecules; identifying 500 bp windows within the DNA molecules; isolating from the genomic DNA molecules the fragments that have a size from 500 pb up 6000 pb; selecting a DNA replication origin that is able, when contained in the DNA of an Eukaryotic cell, to produce nascent DNA, and to initiate DNA replication; and isolating the origin.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

A signal tracking system including: one fixation element to be secured to a rigid body part of the patient surrounding a target body part, the fixation element further including a mapping element, one tracker element to be secured to the fixation element to track, in real time, the internal tracker, and a control unit including a memory to store an internal referential and one image displaying the target body part and one fixation element. The control unit is designed to define, inside the internal referential, at least one 3D frame position attached to the at least one fixation element, and to precisely locate each point of the target body part, the control unit is further designed to precisely localize, in real time, the internal tracker inside the target body part.

IPC Classes  ?

• A61B 5/06 - Devices, other than using radiation, for detecting or locating foreign bodies
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• A61B 34/20 - Surgical navigation systems; Devices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis

Abstract

The invention relates to recombinant measles virus expressing Immunodeficiency virus (IV) or HTLV polypeptides, and concerns in particular immunogenic immunodeficiency virus particles expressed by a measles virus and/or virus like particles (VLPs) that contain proteins of at least one immunodeficiency virus or Human T-lymphotropic virus. These particles may be recombinant infectious particles able to replicate in a host after an administration. The invention provides means, in particular nucleic acid constructs, vectors, cells and rescue systems to produce these recombinant infectious particles. The invention also relates to the use of these recombinant infectious particles, in particular under the form of a composition, more particularly in a vaccine formulation, for the treatment or prevention of an infection by HIV or HTLV.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• A61P 31/18 - Antivirals for RNA viruses for HIV
• C07K 14/15 - Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
• C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof

Abstract

A method for the detection of polycyclic aromatic hydrocarbons including: a) a step of contacting an aqueous solution including at least one polycyclic aromatic hydrocarbon with a catalyst for the oxidation of polycyclic aromatic hydrocarbons and with an electrode made of a conductive porous material, and b) a step of detecting the anthraquinone that is formed during the previous step through the oxidation of the polycyclic aromatic hydrocarbons.

IPC Classes  ?

• C12Q 1/26 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
• C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions

Abstract

The invention relates to a process for programing a single cell or a group of cells to become malignant, comprising the following steps a) providing cell(s) with the following features: o expressing a dedifferentiation factor, and o comprising an oncogene whose expression is inducible, and b) inducing the expression of said oncogene.

IPC Classes  ?

• A01K 67/027 - New breeds of vertebrates
• C07K 14/82 - Translation products from oncogenes
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

The invention relates to a method for bringing a virtual three-dimensional model of a target organ, which model is called the 3D model, into register with at least one image of said target organ in a scene, said image being obtained by an endoscope (12), the method in particular comprising: a step of predicting a position and orientation of the target organ relative to the scene; a step of superposing at least one current endoscope image with a see-through projection of the 3D model as a function of the predicted position and orientation, on a display device (18); a step of receiving a command indicating an alignment between the see-through projection of the 3D model and the image of the target organ in the current image; and a step of computing the position and orientation of the target organ in the current image relative to the scene.

IPC Classes  ?

• G06T 7/33 - Determination of transform parameters for the alignment of images, i.e. image registration using feature-based methods

Abstract

Device (10) capable of being installed on a satellite (1), comprising telecommunication means (13) for broadcasting information directly to at least one telecommunication terminal (2) on the ground. The information is broadcast according to a Bluetooth Low Energy protocol, and in AD mode. The device can be used in particular for an Earth observation satellite.

IPC Classes  ?

• H04W 4/06 - Selective distribution of broadcast services, e.g. multimedia broadcast multicast service [MBMS]; Services to user groups; One-way selective calling services
• H04W 4/90 - Services for handling of emergency or hazardous situations, e.g. earthquake and tsunami warning systems [ETWS]
• H04B 7/185 - Space-based or airborne stations
• H04W 56/00 - Synchronisation arrangements

Abstract

The invention relates to a method for producing an abradable ceramic composite coating on a substrate, the method comprising: obtaining (E1) a composition (30) in powder form comprising a matrix powder and a ceramic filler hydrated precursor powder having a lamellar crystallographic structure, wherein the ceramic filler powder represents from 5 to 40% of the combined volume of the matrix powder and the ceramic filler powder; compressing the prepared powder composition at a pressure greater than 150 MPa; and a step of reactive sintering (E2) the obtained powder composition, during which the pressure is maintained at a temperature of less than 550°C, and the particles of the matrix powder in the sintered powder composition have an aspect ratio of 2 or greater. The invention also relates to an abradable ceramic coating obtained according to the method. The invention also relates to a superalloy part for a turbomachine, for example a turbine part, comprising such a coating.

IPC Classes  ?

• C04B 41/00 - After-treatment of mortars, concrete, artificial stone or ceramics; Treatment of natural stone
• C04B 35/488 - Composites
• C04B 35/486 - Fine ceramics
• C04B 35/622 - Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
• C04B 35/645 - Pressure sintering
• C04B 38/00 - Porous mortars, concrete, artificial stone or ceramic ware; Preparation thereof
• C04B 41/52 - Multiple coating or impregnating
• C04B 41/87 - Ceramics
• C04B 41/89 - Coating or impregnating for obtaining at least two superposed coatings having different compositions
• B32B 18/00 - Layered products essentially comprising ceramics, e.g. refractory products
• F01D 11/12 - Preventing or minimising internal leakage of working fluid, e.g. between stages for sealing space between rotor blade tips and stator using a rubstrip, e.g. erodible, deformable or resiliently biased part
• C23C 24/08 - Coating starting from inorganic powder by application of heat or pressure and heat
• F01D 25/00 - Component parts, details, or accessories, not provided for in, or of interest apart from, other groups
• C04B 111/00 - Function, property or use of the mortars, concrete or artificial stone

Abstract

The present invention relates to an expression cassette allowing expression of a functional LRIT3 protein in mammal eyes; said expression cassette is inserted in an expression vector, preferably an adeno-associated virus (AAV); accordingly, the present invention further relates to a recombinant adeno-associated virus (AAV) vector carrying a nucleic acid sequence encoding a normal LRIT3 gene, or fragment thereof, under the control of regulatory sequences which express the product of the gene in the ocular cells, a pharmaceutically acceptable composition comprising such a recombinant AAV vector and to its use for the treatment of congenital stationary night blindness

IPC Classes  ?

• C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• A61P 27/02 - Ophthalmic agents
• C12N 15/86 - Viral vectors

Abstract

An optomechanical transducer, including a tuning fork made of piezoelectric material including two arms, at least one photoactive film partially deposited on at least one part of at least one of the arms of the tuning fork, the at least one photoactive film including photo-switchable molecules, suitable for molecular switching between a first molecular configuration and a second molecular configuration in response to the absorption of light at a defined, so-called photo-isomerisation wavelength, so that the photoactive film undergoes a shape change that induces a change in the stiffness coefficient of the tuning fork is disclosed. A probe is also provided for a frequency modulation atomic force microscope and to such a microscope.

IPC Classes  ?

• G01Q 10/04 - Fine scanning or positioning
• C09J 4/00 - Adhesives based on organic non-macromolecular compounds having at least one polymerisable carbon-to-carbon unsaturated bond
• G01Q 60/32 - AC mode
• G01Q 70/14 - Particular materials

Abstract

The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, for use as a drug, especially as an antibiotic. The present invention also relates to a pharmaceutical composition comprising said compound of formula (I) and at least one pharmaceutically acceptable excipient. The present invention further concerns a method of preparation of a compound of formula (I′). The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, for use as a drug, especially as an antibiotic. The present invention also relates to a pharmaceutical composition comprising said compound of formula (I) and at least one pharmaceutically acceptable excipient. The present invention further concerns a method of preparation of a compound of formula (I′).

IPC Classes  ?

• C07C 49/747 - Unsaturated compounds containing a keto group being part of a ring containing hydroxy groups containing six-membered aromatic rings
• A61P 31/04 - Antibacterial agents
• C07C 45/59 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only hetero atom in five-membered rings
• C07C 49/753 - Unsaturated compounds containing a keto group being part of a ring containing ether groups, groups, groups, or groups
• C07C 69/738 - Esters of keto-carboxylic acids
• C07D 317/54 - Radicals substituted by oxygen atoms

Abstract

The present invention relates to an in vitro method for preparing a composition comprising mesenchymal stem cells (MSCs) intended for treating ischemia-reperfusion injury, comprising: a) providing MSCs; b) cultivating MSCs in a culture medium comprising a PPARβ/δ agonist; c) removing the culture medium and washing the MSCs; and d) collecting MSCs in a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier does not contain a PPARβ/δ agonist. It further relates to MSCs obtained using the method of the invention, as well as their use as a medicament, preferably in the treatment or prevention of ischemia-reperfusion injury, wherein the method of treatment or prevention does not comprise administering a PPARβ/δ agonist to the subject.

IPC Classes  ?

• A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
• C12N 5/0775 - Mesenchymal stem cells; Adipose-tissue derived stem cells

Abstract

The invention relates to an isolated non-naturally occurring protein comprising the amino acid sequence as set forth in SEQ ID NO: 1, and wherein the amino acid in position 8, 47, 209 and/or 354 is substituted by any amino acid different from the amino acid indicated at that position in said sequence SEQ ID NO: 1.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
• C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof

Abstract

The invention relates to a substrate coated with a coating consisting of molybdenum (Mo), sulfur (S), tantalum (Ta) and oxygen (O) atoms present in the form of one or several compound(s) selected from among the compounds of formula (I): The invention relates to a substrate coated with a coating consisting of molybdenum (Mo), sulfur (S), tantalum (Ta) and oxygen (O) atoms present in the form of one or several compound(s) selected from among the compounds of formula (I): MowSxTayOz  (I) wherein w is equal to 0 or 1; x varies from 0 to 2; y varies from 0 to 1 and z varies from 0 to 3; said coating comprising at least 5% at of oxygen and said coating having a dense compact microstructure.

IPC Classes  ?

• C10M 103/06 - Metal compounds
• C01G 39/00 - Compounds of molybdenum
• C23C 14/06 - Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material characterised by the coating material
• C23C 14/35 - Sputtering by application of a magnetic field, e.g. magnetron sputtering

Abstract

The present invention relates to the treatment of cancer. Here, the inventors identified a subset of prostate cancer patients showing an up-regulation of the epigenetic enzymes SUV4-20H1 and SUV4-20H2, two methyltransferases responsible for the di- and tri- methylation of histone H4 at lysine 20 (H4K20me2/3). Consistent with this, the inventors demonstrate that the pharmacological inhibition of both SUV4-20H1 and SUV4-20H2 enzymes by the chemical compound A196 (14) leads to the complete loss of H4K20me2/3 states in prostate cancer cells. Although displaying epigenetic reprograming at genome-wide levels, cancer cells display any significant impairment in their survival or proliferation, thereby demonstrating that the inhibition of SUV4-20H1 and SUV4-20H2 is not toxic per se. Yet, the inventors showed that the pharmacological inhibition of SUV4-2H1 and SUV4-20H2 subtly affects DNA repair mechanisms and the levels of trapped topoisomerase II (TOPO2) complex in silent chromatin regions upon TOPO2 poisons. This creates in vitro as well as in vivo a lethal synergy between A196 and the TOPO2-poison etoposide in prostate cancer cells. Altogether, the results of the inventors showed that the simultaneous inhibition of SUV4-20H and TOPO2 enzymatic activity constitutes indeed a new therapeutic approach for the treatment of advanced or metastatic prostate cancers, which are particularly addicted to SUV4-20H2 and TOPO2 activities. Other cancers could also benefit of this drug combination, since the co-treatment of A196 and etoposide induces similar lethal synergy in other epithelial cancer cells such as breast cancer cell lines. Thus, the present invention relates to a combination of a SUV4-20H inhibitor and a TOPO2 inhibitor for use in the treatment of a cancer in a subject in need thereof.

IPC Classes  ?

• A61K 31/136 - Amines, e.g. amantadine having aromatic rings, e.g. methadone having the amino group directly attached to the aromatic ring, e.g. benzeneamine
• A61K 31/501 - Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to triblock polymers of formula A-B-C, in which the symbol A represents a polystyrene block, the symbol B represents a statistical copolymer block having a glass transition temperature of less than -10° C, the statistical copolymer comprising units of a 1,3-diene and more than 50 mol % of ethylene units, and the symbol C represents a polyethylene block having a melting temperature higher than 90°C. The triblock polymers according to the invention have good elastic recovery.

IPC Classes  ?

• C08F 295/00 - Macromolecular compounds obtained by polymerisation using successively different catalyst types without deactivating the intermediate polymer
• C08F 210/02 - Ethene
• C08F 297/08 - Macromolecular compounds obtained by successively polymerising different monomer systems using a catalyst of the ionic or coordination type without deactivating the intermediate polymer using a catalyst of the coordination type polymerising mono-olefins
• C08L 53/00 - Compositions of block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds; Compositions of derivatives of such polymers

Abstract

Among the strategies allowing cancer cells to escape the immune system, the presence of Transforming growth factor beta (TGF-β) in the tumor micro-environment (TME) is one of the most potent immunosuppressive mechanisms for many types of tumors. Thus, depleting TGF-β is regarded as a promising potent therapeutic approach to fight cancers, regardless of the type of tumor. However, the major impediment for achieving this objective is that TGF-β belongs to the few cytokines that must be activated once secreted. Moreover, a systemic targeting of TGF-β is associated with profound side effects due to TGF-β ability to sustain the homeostasis of numerous tissues. Hence, selectively targeting of TGF-β activation within the TME appears as a rational approach to boost the anti-tumor response and avoid side effects. The integrin αvβ8 expressed on Tregs specifically promotes TGF-β activation and impairs the anti-CD8 T cell response within the TME of different cancers in both mice and humans. The inventors generated anti-β8 chain of αvβ8 integrin (Itgβ8) neutralizing monoclonal antibodies which specifically bind to Tregs and selectively neutralize the ability of Tregs to activate the TGF-β. Thus, the present invention relates to isolated anti-Itgβ8 neutralizing antibodies which specifically binds to β8 chain of αvβ8 integrin (Itgβ8) expressed on Tregs, and their uses for treating cancer.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

in vitroex vivoin vitroex vivoex vivo diagnosis of bacterial resistance by efflux, as well as specific coumarin derivatives for this use.

IPC Classes  ?

• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
• C12Q 1/18 - Testing for antimicrobial activity of a material

Abstract

The invention relates to a device for spraying ozonated water in an agricultural environment, the device comprising a collar defining a dispensing opening (4) for dispensing both water and ozone together, the water being sprayed by a nozzle (10) set back from the opening, the nozzle being supplied from a tank (7) installed with the device, the ozone gas being dispensed via a gas inlet (22) connected to a device for producing and/or storing gas (9, 13) which is also installed with the device, the gas inlet also being set back in the collar such that the collar defines a chamber (28, 29) for confining the ozone gas emitted around the sprayed liquid in order to allow the sprayed liquid to be enriched with dissolved ozone.

IPC Classes  ?

• B05B 7/04 - Spray pistols; Apparatus for discharge with arrangements for mixing liquids or other fluent materials before discharge
• B05B 1/34 - Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl
• A61L 2/22 - Phase substances, e.g. smokes, aerosols
• A61L 9/14 - Disinfection, sterilisation or deodorisation of air using sprayed or atomised substances
• B05B 1/04 - Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to produce a jet, spray, or other discharge of particular shape or nature, e.g. in single drops in flat form, e.g. fan-like, sheet-like

Abstract

The present invention relates to a polynucleotide comprising a gene encoding a hook protein and a gene encoding a protein of interest, said protein of interest being either a secretory protein or a cell membrane-anchored protein, wherein: said gene encoding the hook protein is under the control of a first transcription-activating signal, said gene encoding the protein of interest is under the control of a second transcription-activating signal, said second transcription-activating signal allowing a lower rate or frequency of transcription initiation than the first transcription-activating signal, said hook protein is fused to a cellular compartment-retention peptide, and said protein of interest is fused to a hook protein-binding domain The present invention relates to a polynucleotide comprising a gene encoding a hook protein and a gene encoding a protein of interest, said protein of interest being either a secretory protein or a cell membrane-anchored protein, wherein: said gene encoding the hook protein is under the control of a first transcription-activating signal, said gene encoding the protein of interest is under the control of a second transcription-activating signal, said second transcription-activating signal allowing a lower rate or frequency of transcription initiation than the first transcription-activating signal, said hook protein is fused to a cellular compartment-retention peptide, and said protein of interest is fused to a hook protein-binding domain It also related to vectors comprising the polynucleotide, cells comprising the polynucleotide or the vector and compositions comprising the same. It further relates to methods and uses for modulating the secretion or cell membrane-anchorage of a protein of interest, or for preventing and/or treating a disease in a subject in need thereof.

IPC Classes  ?

• C12P 21/00 - Preparation of peptides or proteins
• C07K 14/36 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptomyces (G)
• C07K 14/54 - Interleukins (IL)
• C07K 14/55 - IL-2
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

Disclosed is a compound having the following formula (I): Disclosed is a compound having the following formula (I): as well as to the use of such as a dye sensitizer. Disclosed is a compound having the following formula (I): as well as to the use of such as a dye sensitizer. Also disclosed is a dye sensitized solar cell including at least one compound of formula (I) as dye sensitizer.

IPC Classes  ?

• C07F 5/02 - Boron compounds
• B01J 21/06 - Silicon, titanium, zirconium or hafnium; Oxides or hydroxides thereof
• B01J 31/38 - Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups of titanium, zirconium or hafnium
• B01J 35/00 - Catalysts, in general, characterised by their form or physical properties
• C09B 23/01 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain
• H01G 9/20 - Light-sensitive devices

Abstract

The present invention relates to a process for producing a stable PVDF latex by emulsion polymerization in the absence of fluorinated surfactant, said latex being stabilized by poly(vinyl alcohol) (PVOH).

IPC Classes  ?

• C08F 14/22 - Vinylidene fluoride
• C08F 261/06 - Macromolecular compounds obtained by polymerising monomers on to polymers of oxygen-containing monomers as defined in group on to polymers of unsaturated ethers
• C08L 27/16 - Homopolymers or copolymers of vinylidene fluoride
• C09D 127/16 - Homopolymers or copolymers of vinylidene fluoride
• C08L 29/04 - Polyvinyl alcohol; Partially hydrolysed homopolymers or copolymers of esters of unsaturated alcohols with saturated carboxylic acids
• C08F 2/20 - Suspension polymerisation with the aid of macromolecular dispersing agents

Abstract

The present invention concerns a method and a system of fault tolerant preparation of quantum polar code states, comprising: -a set of single qubit Pauli measurement circuits (3) configured to prepare an initial quantum system 5 of N = 2n single-qubit states associated to an initial quantum base, -a set of two qubit Pauli measurement circuits (7) configured to recursively prepare a quantum polar code |q2n)s °f codelength N = 2n, wherein at each recursive level k, where k = 1 to n, a set of 2n/2k quantum polar code states ||<72fc) j(k) = 1 to 2n/2k of codelengths 2k, siW referenced by corresponding sets Sj^ of indices comprising first and second sets of frozen indices = [17, ■ ■■, i7(k)} and X7(k) = {(i + !);(/<),..., 27k k)} is prepared, each quantum polar code state |q2k) being prepared by the application of two qubit Pauli measurement P ® P circuits on two equivalent polar code states 2^ ) 01 aanndd belonging to the output of the antecedent recursive level k — 1 and referenced by two corresponding sets of iinnddiicceess

IPC Classes  ?

• G06N 10/20 - Models of quantum computing, e.g. quantum circuits or universal quantum computers
• G06N 10/70 - Quantum error correction, detection or prevention, e.g. surface codes or magic state distillation
• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control

Abstract

The invention relates to an angular positioning module (1) for a positioning system for an optical bench, the angular positioning module (1) comprising: a fixed frame (5); a rotating shaft (7); a rotary motor (11); a transmission device (17) being provided with a pulley (19) mounted on the output rod (13) of the rotary motor (11) so as to be coupled in rotation therewith, with a wheel (21) mounted on the rotating shaft (7) so as to be coupled in rotation therewith, and with a cable wound on the one hand around the pulley (19) and on the other hand around the wheel (21) such that the pulley (19) and the wheel (21) are connected by two separate strands of the cable, the rotation of the pulley (19) causing the winding of a first strand and the simultaneous unwinding of a separate second strand around the pulley (19), and vice versa.

IPC Classes  ?

• G02B 7/00 - Mountings, adjusting means, or light-tight connections, for optical elements
• F16H 19/06 - Gearings comprising essentially only toothed gears or friction members and not capable of conveying indefinitely-continuing rotary motion for interconverting rotary motion and reciprocating motion comprising an endless flexible member

Abstract

The invention relates to an electrical energy storage module (M1-ln) which comprises a plurality of elementary storage cells (C1 to C12). According to the invention, the module comprises at least one cell unit (U1-1, U1-2) including a plurality of elementary storage cells connected in series (C1 to C6; C7 to C12) and integrated power-switching means (P1, S1; P2, S2) dedicated to this cell unit, delivering, between two power output terminals (B1, B2) of the cell unit, a positive DC voltage, a negative DC voltage, a zero voltage or a high impedance state, depending on a command received by the cell unit.

IPC Classes  ?

• H01M 10/42 - Methods or arrangements for servicing or maintenance of secondary cells or secondary half-cells

Abstract

The invention relates to a method implemented by computer means for characterizing at least one organ of a patient in at least one medical image, said method comprising the following iterative steps of: segmenting (6) said organ in at least one image (7) representing a healthy organ, so as to obtain at least one segmentation mask (8) of said healthy organ, generating additional segmentation masks of said healthy organ, using at least one data augmentation method (9) on the basis of the segmentation mask obtained in step (a), said data augmentation method (9) being a shape-preserving method, training an autoencoder (10) with the segmentation mask obtained in step (a) and the additional segmentation masks obtained in step (b) to encode the shape of said organ in a latent space (11 ).

IPC Classes  ?

• G06T 7/00 - Image analysis

Abstract

Disclosed is a pharmaceutical composition that contains at least one compound with the following formula (I) as active ingredient: in which R1 is chosen from H, SO3−, R2 is chosen from H and COCH3, R3 is chosen from H, Disclosed is a pharmaceutical composition that contains at least one compound with the following formula (I) as active ingredient: in which R1 is chosen from H, SO3−, R2 is chosen from H and COCH3, R3 is chosen from H, COCH3, benzyl, SO3− and pharmaceutically acceptable salts of the compounds—with the exception of the compound of formula (I) in which R1=SO3− and R2=COCH3 and R3=H and of the sodium salt of the compound—and at least one pharmaceutically acceptable excipient. Also disclosed are an associated kit including a biocompatible medium and methods for treatment.

IPC Classes  ?

• C07H 5/06 - Aminosugars
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/02 - Inorganic compounds
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Abstract

A microfluidic device comprising: —a first wall comprising a first substrate on which a plurality of closed patterns is grafted, —a second wall, facing the first wall, comprising a second substrate, —a plurality of nucleic acids grafted either on the first substrate or on the second substrate, wherein each nucleic acid comprises a barcode that encodes the position of the nucleic acid on said first or second substrate, wherein at least the plurality of closed patterns or the second substrate is made of an actuatable hydrogel which is swellable between a retracted state and a swollen state in which the closed patterns and the second substrate come into contact.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers

Abstract

Nanostructured surface coating (1) configured to generate visual appearances in a visible spectrum range, comprising: —a first layer comprising a random distribution of nanoparticles (2); —a substrate (3), on which the first layer is arranged; —the nanoparticles having an optical refraction index npart having a value suitable for each individually diffusing the incident light; —the nanoparticles being arranged so that the mean distance between two adjacent particles d is defined in accordance with the following relationship so as to produce interference between the light diffused by the particles: 2 R≤d≤max (λ/np), where R is the smallest geometric radius of a circle surrounding the particle, λ is the greatest wavelength of the visible spectrum, and np is the optical refractive index of the medium in which the nanoparticles are dispersed.

IPC Classes  ?

• G02B 5/02 - Diffusing elements; Afocal elements

Abstract

The present disclosure relates to a time client device comprising a network interface for communicating over a communication network, the time client device being configured to: receive, over the communication network from an authentication server (AS), a first key, and a first value containing the first key in encrypted form; generate a second value using the first key; and during a time synchronization phase, transmit to a time server (TS) the first and second values.

IPC Classes  ?

• H04L 9/32 - Arrangements for secret or secure communications; Network security protocols including means for verifying the identity or authority of a user of the system

Abstract

(n)jn(n)1(n)2(n)2(n) associated with each useful output (15u) and defined when the light source (11) is inactive.

IPC Classes  ?

• G01N 21/27 - Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection
• G01N 21/77 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
• G01B 9/02 - Interferometers
• G01N 21/45 - Refractivity; Phase-affecting properties, e.g. optical path length using Schlieren methods

Abstract

The present invention relates to the use of an aminoborane for the preparation of an alkenylaminoborane from a catalyst-free alkyne or in the presence of a catalyst selected from the group of acids consisting of carboxylic acids, sulfonic acids, sulfuric acid, phosphonic acids, phosphoric acid and hexafluoroisopropanol (HFIP), in particular acetic acid, benzoic acid and 4-(dimethylamino) benzoic acid, methylsulfonic acid, phosphoric acid, trifluoroacetic acid (TFA) and hexafluoroisopropanol (HFIP), and a preparation method therefor.

IPC Classes  ?

• C07F 5/02 - Boron compounds
• C07F 7/08 - Compounds having one or more C—Si linkages
• C08K 5/55 - Boron-containing compounds

Abstract

Advanced cutaneous melanoma can be treated by immunotherapy targeting immune check points such as PD-1 and CTL-A4. However, 50% of patients do no respond because of primary or acquired resistance mechanism. Thus, new targets for addressing the treatment of said resistance are highly needed. The inventors show that TNF (Tumour Necrosis Factor) and ceramide metabolism alterations in melanoma cells contribute to melanoma progression and resistance to immunotherapies. In particular, the inventors demonstrate that TNF is a potent modulator of ceramide metabolism and TNF-mediated ceramide metabolism changes contribute to various biological processes such as cell proliferation, cell death and cell differentiation. Among the biological processes by which TNF triggers melanoma immune escape and resistance to immunotherapies, TNF triggers a dedifferentiation process of melanoma cells associated with the reduction of melanocytic antigen expression and epithelial to mesenchymal transition. Finally, the inventors show that glycosphingolipid pattern in plasma can predict the clinical outcome of advanced melanoma treated with ipilimumab and nivolumab. Accordingly, ceramide metabolites and metabolizing-enzymes can be new therapeutic targets and/or biomarkers in advanced melanoma patients treated with immunotherapies.

IPC Classes  ?

• A61K 31/225 - Polycarboxylic acids
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to a magnetic component comprising a substrate (6) supporting at least one pair of permanent magnets (2) extending in a first direction (X), each magnet (2) having an interaction end (21a, 21b), the interaction ends (21a, 21b) being arranged facing one another, the pair of magnets (2) being arranged so as to exert an antisymmetric magnetic field with a high magnetic field gradient along a second direction (Z) orthogonal to the first direction (X), under the effect of a magnetic field produced by external magnetic means.

IPC Classes  ?

• H01F 41/34 - Apparatus or processes specially adapted for manufacturing or assembling magnets, inductances or transformers; Apparatus or processes specially adapted for manufacturing materials characterised by their magnetic properties for applying conductive, insulating or magnetic material on a magnetic film in patterns, e.g. by lithography
• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control

Abstract

The invention relates to a method for characterising the deformability of cells or a portion of cells in a sell sample, the method comprising: • - culturing the cells on a microstructured plate having microgrooves with a predetermined width and depth for at least partially engaging the nuclei of the cells in one or more microgrooves, at least one portion of the surface of the microgrooves being a cell adhesion surface; • - measuring a fluorescence signal of the nuclei, which nuclei are pre-treated so as to emit fluorescence radiation; • - on the basis of the fluorescence signal measured for each nucleus, determining a fluorescence intensity profile and at least one morphological parameter of the nucleus; • - on the basis of the fluorescence intensity profile and the at least one morphological parameter, determining a deformation class of the nucleus in the depth of the microgrooves.

IPC Classes  ?

• G01N 15/14 - Electro-optical investigation
• G01N 33/49 - Physical analysis of biological material of liquid biological material blood

Abstract

A thermal energy storage device (1) comprises a storage unit, formed by a reservoir (3) for receiving a thermal energy storage material (5) and a closure device (2) configured to close the opening of the reservoir, and a sealing system for sealing the storage unit, said thermal energy storage material (5) consisting of anhydrous lithium hydroxide having a purity greater than 96% or lithium hydroxide monohydrate with a purity greater than 56%.

IPC Classes  ?

• F28D 20/02 - Heat storage plants or apparatus in general; Regenerative heat-exchange apparatus not covered by groups or using latent heat
• C09K 5/06 - Materials undergoing a change of physical state when used the change of state being from liquid to solid or vice-versa

Abstract

A method for stripping U(VI) and an An(IV) from an organic solution including tri-n-butyl phosphate in an organic diluent, the solution containing U(VI) and the An(IV) present as U(VI) nitrate and An(IV) nitrate at concentrations such that the U(VI) nitrate concentration is higher than the An(IV) nitrate concentration, and the sum of the U(VI) nitrate and An(IV) nitrate concentrations is ≥55 g/L. The method includes contacting the organic solution and an aqueous solution of nitric and oxalic acids, the oxalic acid concentration in the aqueous solution and the O/A volume ratio selected so that the oxalic acid is deficient with respect to the stoichiometric conditions of a complete precipitation of U(VI) and actinide(IV), to obtain a precipitate containing the actinide(IV) in oxalate form and a fraction of the U(VI) in oxalate form with a U(VI)/actinide(IV) mass ratio of between 0.5 and 5; and separating the precipitate from the organic and aqueous solutions.

IPC Classes  ?

• G21F 9/12 - Processing by ion-exchange

Abstract

Disclosed is a mixing device including a chamber defining a circulation zone, the circulation zone including at least one base liquid and a mixing fluid, the mixing fluid being less paramagnetic than the base liquid, the mixing fluid including and/or consisting of at least one first fluid, the mixing device including at least one magnetic element which generates a magnetic field in the circulation zone so that the mixing fluid flows into the base liquid, the chamber including at least one first injection point of the first fluid into the circulation zone, the first injection point opening into the base liquid.

IPC Classes  ?

• B01F 25/31 - Injector mixers in conduits or tubes through which the main component flows
• B01F 25/314 - Injector mixers in conduits or tubes through which the main component flows wherein additional components are introduced at the circumference of the conduit
• B01F 33/451 - Magnetic mixers; Mixers with magnetically driven stirrers wherein the mixture is directly exposed to an electromagnetic field without use of a stirrer, e.g. for material comprising ferromagnetic particles or for molten metal

Abstract

12344 are independently a hydrogen atom or an alkyl group, A is an alkylene group, and the total number of carbon atoms in the surfactant compound of formula (I) is from 10 to 24.

IPC Classes  ?

• B65G 5/00 - Storing fluids in natural or artificial cavities or chambers in the earth
• E21B 41/00 - Equipment or details not covered by groups
• C09K 8/584 - Compositions for enhanced recovery methods for obtaining hydrocarbons, i.e. for improving the mobility of the oil, e.g. displacing fluids characterised by the use of specific surfactants
• C09K 8/594 - Compositions used in combination with injected gas